Pharma & Life Science Consulting Services

The age of blockbusters is over; the solution lies in the 4 Ps: personalised, participatory, preventive and predictive. With Zühlke as your partner, you can boldly drive this development forward – with digital, data-driven solutions that add value for you and your patients.

Let's tackle your challenges together

  • Apps and devices for personalised medicine

    In the healthcare market of tomorrow, the key to success will be applying pharmaceutical and health tech expertise to unmet patient need. The future will belong to innovative solutions spanning the entire patient journey and – crucially – which deal with patient data responsibly.

    Learn more
  • Digital solutions that patients trust

    Machine learning algorithms represent an exciting approach for realising new products and services or for process optimisation. Realising the potential offered by machine learning requires platforms that enable secure, legal, privacy-preserving use of anonymised health data.

    Learn more
  • DTx: Software as therapeutics

    With no side effects and high scalability, digital therapeutics (DTx) boast enormous potential – including for pharmaceutical companies. That’s because software that is used as a therapeutic product is able to target new customer groups and enable completely new business and payment models.

    Learn more
  • Smart sensors enable innovative therapies

    Whether it’s clinical trials or pay for performance, as digitalisation of the healthcare system progresses, continuous monitoring of therapeutic progress and outcomes is set to become increasingly important. That necessitates smart, reliable sensors able to measure and transmit biomarker information.

    Learn more
  • Boosting the efficiency of clinical trials

    For pharmaceutical companies, clinical trials represent a significant cost. GxP-compliant data platforms can help companies design safe, reliable trials in the shortest possible time, and help them find the right participants.

    Learn more

Big tech has inserted itself into every aspect of our lives and is collecting user data on an unprecedented scale. This throws up some major challenges for pharmaceutical companies. Patients, health insurers and society in general expect ever more – from more personalised medicine to complementary digital health services, to outcome-based payment models (pay for performance). 

Zühlke offers both extensive expertise in the development of large B2C consumer platforms and more than 50 years of experience in the healthcare sector. We’re developing apps and devices for the next phase of personalised healthcare, and helping pharmaceutical companies position themselves to play a lead role in tomorrow’s digitalised healthcare system. 

Pharmaceutical company Chugai Pharmaceuticals wanted to launch new digital services in Europe. Zühlke developed a range of strategy options:

Machine learning algorithms enable the development of exciting new products and services and well as improving therapy selection and process acceleration through the use of genetic or real-world data. In addition to our expertise in machine-learning algorithms, Zühlke also develops platforms to enable secure, legal use of anonymised health data – an important basis for research and development as well as a positive digital experience for patients. 

That requires trust between patients, researchers and the companies providing these solutions – which Zühlke achieves by giving patients complete control over their health data. To realise this, we bring together user-centric healthcare apps for patients, data security expertise, advanced machine-learning techniques like federated learning, and insights from the behavioural sciences.

AO Foundation and Zühlke employed cutting edge privacy-preserving AI techniques to develop automated image segmentation solutions for spinal CT scan images:

Drugs sometimes have serious side effects that can be highly onerous for patients. Digital therapeutics (DTx) offer huge potential for addressing this problem, for example in areas such as mental health.

Zühlke can help you realise your digital healthcare ideas – from feasibility studies through to operation of your solution. The result is software as a medical device (SaMD) products capable of supplementing or even replacing existing therapies and diagnostic procedures. Enabling pharmaceutical companies to target new customer groups and develop completely new business and payment models (in Germany, for example, through digital health and digital care apps). 

And, in contrast to conventional drugs, bringing digital therapeutics to market is quick, simple and easily rolled out globally. We help you grasp this opportunity with secure, patient-centric apps that comply with exacting medical standards like IEC 62366-1.

Zühlke can help you realise your digital healthcare ideas. From feasibility studies through to operation of your solution, as with our exemplary work on the UK National Health Service COVID-19 app:

In today’s healthcare, proving the efficacy of a new drug through clinical trials is no longer sufficient – you need to prove beyond doubt that it’s superior to existing treatments. As with outcome-based payment models (pay for performance), pharmaceutical companies are increasingly required to measure the benefits of a therapy in real time.

We can help you achieve this by, for example, developing smart sensors for measuring digital biomarkers. Our solutions are always based on established processes and subject to constant controls during development. We also help you exploit your harvested data – whether by developing and operating a full scale digital data platform, by using machine learning to extract valuable information from your captured data or by using user-friendly apps to add patient reported outcomes (PRO) to your data pool.

Delivering improved products and enabling new services increasingly means building connectivity into medical devices. Zühlke delivered an end-to-end concept for a new connectivity system:

With overcomplicated registration processes and high drop-out rates, clinical trials are often inefficient and time-consuming. So much so that clinical trials can consume up to 50 percent of a pharmaceutical company’s R&D budget. By helping pharmaceutical companies identify suitable participants and making it easier for participants to take part in trials, digital technologies have the power to solve this problem. Zühlke’s GxP-compliant data platforms enable safe, reliable trials to be designed in the shortest possible time.

Using our AI expertise, we can help you extract key information from your harvested data. And we enhance the participant experience by offering attractive apps and user-friendly participant portals – bringing you closer to your patients, but also closer to doctors and other healthcare professionals. And we make sure our solutions meet the highest security standards, boosting trust in your company.

Professional microphone with blurry stage lights in the background

Data Today: the data podcast for today's innovators

Join us to learn how inspiring individuals from diverse fields and industries are transforming the way they work with data to realise their greatest opportunities. Learn more about data transparency and education in the episode with Anne Thielen.

DHP Whitepaper

Whitepaper "Digital Health Platforms"

The life sciences and healthcare industries are producing an ever increasing amount of data – DHPs hold the key to harnessing it.

Guitar with zühlke logo

Stay connected with us

Subscribe to receive the latest news, insights and exclusive event invitations from Zühlke.

Contact person for Germany

Jürgen Pronebner

Regional Managing Director Health Industry, EMEA & Partner

As one of the first employees at Zühlke Germany, Jürgen Pronebner has helped to shape the Zühlke journey. Currently he acts as Regional Managing Director Health Industry, EMEA. He is a Member of the Zühlke Ventures Advisory Board and a long-time Partner in the Zühlke Group.

Thank you for your message.
Contact person for Austria

Helmut Taumberger

Managing Director Cross Markets, Austria

With his years of experience and a strong innovative mindset, Helmut Taumberger is digital transformation personified. As a Managing Director Cross Markets in Austria, he is responsible for steering the company’s strategic orientation and development. A qualified engineer, he has worked in the IT sector since 2003 and has lent his substantial expertise to various international businesses. He likes nothing more than coming up with practical strategies and getting people excited about technological change.

Thank you for your message.
Contact person for Singapore

Jim Lim

Managing Director Health Singapore

With more than 25 years of ICT industry experience, Jim brings a wealth of experience providing business and strategic advice to clients regionally. Having held various leadership positions across enterprises, Jim was also the founding CEO of Good Doctor Technology. Jim has worked with clients across multiple industry verticals, including healthcare and pharmaceutical. As Head of Health Industry Singapore, Jim will expand Zühlke’s healthcare expertise and offerings to healthcare and pharmaceutical companies in Singapore. 

Thank you for your message.
Contact person for Switzerland

Bardia M. Zanganeh

Director Business Development

Bardia M. Zanganeh serves leading healthcare institutions on all technology agenda issues. His primary areas of focus include digital innovation, business model transformation and product innovation. He has a background in engineering, consulting and entrepreneurship and is a lecturer at the University of Applied Sciences in Business Administration in Zurich. He is driven by the positive impact of technology to reimagine healthcare for better patient outcomes.

Thank you for your message.
Contact person for United Kingdom

Myles Davidson

Head of Sales Excellence UK & Partner

Myles Davidson is an experienced leader for the digital transformation of companies and product innovation. Significant experience in driving business initiatives on a local and international level in a complex and rapidly changing environment. Myles is known as trusted advisor for clients at C- and board-level for strategic questions around business innovation and technology.

Thank you for your message.